Relay Net Tangible Assets from 2010 to 2024

RLAY Stock  USD 4.75  0.11  2.37%   
Relay Therapeutics Net Tangible Assets yearly trend continues to be fairly stable with very little volatility. Net Tangible Assets are likely to outpace its year average in 2024. Net Tangible Assets is the total assets of Relay Therapeutics minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2010-12-31
Previous Quarter
1.1 B
Current Value
1.1 B
Quarterly Volatility
536.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 32.6 M, Interest Income of 32.6 M or Depreciation And Amortization of 4 M, as well as many indicators such as Price To Sales Ratio of 50.19, Dividend Yield of 0.0 or PTB Ratio of 1.0. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Relay Therapeutics Correlation against competitors.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

Latest Relay Therapeutics' Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of Relay Therapeutics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Relay Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relay Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

Relay Net Tangible Assets Regression Statistics

Arithmetic Mean244,176,979
Geometric Mean235,119,201
Coefficient Of Variation219.74
Mean Deviation482,740,105
Median(110,927,000)
Standard Deviation536,558,422
Sample Variance287894.9T
Range1.3B
R-Value0.83
Mean Square Error97743.9T
R-Squared0.68
Significance0.0001
Slope99,280,590
Total Sum of Squares4030529.2T

Relay Net Tangible Assets History

20241.1 B
20231.1 B
2022947.9 M
2021895.5 M
2020763.3 M
2019-180.4 M

About Relay Therapeutics Financial Statements

Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Tangible Assets1.1 B1.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.